1	TITLE: Outcome Measures Used in Pulmonary Rehabilitation in Patients With Acute
2	Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review
3	RUNNING HEAD: Outcome Measures in Acute Exacerbation of COPD
4	SECTION/TOC CATEGORY: Measurement
5	ARTICLE TYPE: Review
6	AUTHOR BYLINE: Ana L. Oliveira, Alda S. Marques
7	AUTHOR INFORMATION:
8	A.L. Oliveira, MSc, Faculty of Sports, University of Porto, Porto, Portugal.
9	A.S. Marques, PhD, Respiratory Research and Rehabilitation Laboratory, School of Health
10	Sciences, University of Aveiro (ESSUA), Agras do Crasto-Campus Universitário de
11	Santiago, Edifício 30, 3810-193 Aveiro, Portugal. Address all correspondence to Dr Marques
12	at: <u>amarques@ua.pt.</u>
13	KEYWORDS: Chronic obstructive pulmonary disease, pulmonary rehabilitation, applied
14	measurement
15	
16	ACCEPTED: November 3, 2017
17	SUBMITTED: May 15, 2017
10	

Background. Conflicting results about the effects of community-based pulmonary 19 20 rehabilitation in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) exist, possibly because the variety of outcome measures used and the lack of appropriate 21 22 measurement properties hinder the development of pulmonary rehabilitation guidelines. **Purpose.** The purpose of this study was to identify and review the measurement properties of 23 patient-reported outcome measures (PROMs) and clinical outcome measures of AECOPD that 24 25 are used in pulmonary rehabilitation and that can be easily applied in a community setting. Data Sources. PubMed, Web of Science, Scopus, and CINAHL were searched up to July 1, 26 2016. 27 28 Study Selection. Phase 1 identified outcome measures used in pulmonary rehabilitation for AECOPD. Phase 2 reviewed the measurement properties of the identified outcome measures. 29 **Data Extraction.** One reviewer extracted the data and 2 reviewers independently assessed the 30 31 methodological quality of the studies and the measurement properties of the outcome

32 measures by using the Consensus-Based Standards for the Selection of Health Status

33 Measurement Instruments (COSMIN) recommendations.

Data Synthesis. Twenty-three PROMs and 18 clinical outcome measures were found. The
outcome measures most used were the St George Respiratory Questionnaire (n = 15/37
studies) and the 6-minute walk test (n = 21/37 studies). Thirty-two studies described the
measurement properties of 22 PROMs and 7 clinical outcome measures. The methodological
quality of the studies was mostly poor, and the measurement properties were mostly
indeterminate. The outcome measure exhibiting more robust properties was the COPD
Assessment Test.

Limitations. A number of studies were published without the validated search strategy used
and were included *a posteriori*; the fact that 3 studies presented combined results for patients
who were stable and patients with exacerbation, affected the conclusions that can be drawn.

44 Conclusions. A large variety of outcome measures have been used; however, studies on their
45 measurement properties are needed to enhance the understanding of community pulmonary
46 rehabilitation for AECOPD.

48 Chronic obstructive pulmonary disease (COPD) is frequently punctuated by acute

exacerbations (AECOPD).¹ Currently, more than 80% of these events are recommended to be
managed within the community since it can shorten the length of hospital stays and/or avoid
hospital admittance.²

52

Pulmonary rehabilitation is a well-established, evidenced-based intervention, possible to be applied within the community (ie, in nonspecialized community health services, in community centers, or at the patient's home)³⁻⁶ and with potential to prevent and decrease the harmful effects of acute exacerbations.⁷ Costs associated with AECOPD in the United States are estimated in \$7100 per patient/per exacerbation⁸ and recent economic studies have shown that, compared with usual care, community-based pulmonary rehabilitation provides cost savings of \$1098 per patient.⁹

60

Nevertheless, conflicting results regarding the clinical effects of pulmonary rehabilitation in 61 AECOPD have been reported^{10,11} and less than 10% of patients discharged from AECOPD are 62 being referred for pulmonary rehabilitation¹² thus, its implementation is not a common 63 practice. This inconsistency among studies may occur due to the wide variety of outcomes 64 and outcome measures used and/or due to the lack of appropriate measurement properties (ie, 65 reliability, validity and responsiveness) of the outcome measures used in exacerbation 66 periods. It is known that the measurement properties of any outcome measure are population 67 specific¹³ and that patients at distinct phases of their chronic disease (stable/exacerbation) 68 differ in the physiologic and ventilatory mechanisms of their lungs.¹⁴ Therefore, it can be 69 hypothesized that instrument measurement properties will also vary in stable and exacerbation 70 periods. 71

Nevertheless, studies involving pulmonary rehabilitation in patients with AECOPD have been
choosing their outcome measures based on the measurement properties established for stable
patients with COPD,^{15,16} which may hinder the development of pulmonary rehabilitation
guidelines and lead instead to publication of recommendations which lack rigorous
underpinning evidence in exacerbation periods.

78

Additionally, attending to patient's level of fragility during exacerbations, the specificities of
implementing a pulmonary rehabilitation program in a nonspecialized center and some
practical issues, such as the need for specific equipment and sufficient space and time required
to complete testing, especially when more than 1 test at baseline is required, may also
influence the selection of the outcome measure.¹⁷

84

Thus, the 2 aims of this systematic review were to identify patient-reported outcome measures (PROMs) and clinical (non-patient-reported) outcome measures that are used to assess the effects of pulmonary rehabilitation interventions in patients with AECOPD and that can be easily applied in the community (ie, not expensive, not invasive, and quickly implemented) and to synthesize/evaluate their measurement properties.

90

91 Methods

92 This systematic review (PROSPERO registration no. CRD42015023736) was conducted in 2

93 phases. Phase 1 identified outcome measures used to assess outcomes of pulmonary

94 rehabilitation interventions in patients with AECOPD and that can be easily applied in

95 community-based practice. Phase 2 aimed to assess the measurement properties of the

96 identified outcome measures.

97 Phase 1: Measures Used in Pulmonary Rehabilitation

Data sources and searches. The effects of pulmonary rehabilitation interventions in patients
with AECOPD have been largely reviewed,^{10,11,18–21} thus a first search limited to literature
reviews was conducted from May to June 2016 in PubMed, Web of Knowledge, Scopus, and
CINAHL. The original papers included in these reviews were extracted and searched for the
outcome measures.

103

104 The latest available literature review on this theme was dated from 2012 and thus, a second search using the same keywords and databases but limited to original studies published from 105 2010 to June 2016 was also performed to identify all outcome measures most recently used by 106 physiotherapists. An interval of 2 years until the most recent review in the theme seemed 107 appropriate, as studies indicate that time from submission to publication can go up to 2 108 years.²² In both searches, the reference lists of the identified studies were scanned for other 109 110 potential eligible studies. Additionally, a weekly update was conducted until July 2016. The full search strategy can be found in eAppendix 1 (available at: https://academic.oup.com/ptj). 111

Study selection. Selection of studies was performed by 1 reviewer (A.L.O.) and checked by a second reviewer (A.S.M.). After removing duplicates, 1 reviewer (A.L.O.) performed the initial screening of articles based on type of publication and relevance for the scope of the review. Selection of studies checked by a second reviewer (A.S.M.).

116

First, title and abstract were screened, and if the articles were considered relevant, full text was analyzed. Studies were included if they met the following 3 criteria: aimed to assess pulmonary rehabilitation or one of its components; assessed patients with an AECOPD within 3 weeks of the onset as this is the mean time needed for recovery^{2,23,24}; and were written in English, Spanish, French, or Portuguese. Studies were excluded if they were conducted in animals; patients requiring emergency intubation, intensive care unit management, and/or
mechanical ventilation; patients with compromised neurological status or hemodynamic
instability; patients performing self-management programs only; and patients assessed only
after discharge for AECOPD. Book chapters, abstracts of communications or meetings, letters
to the editor, commentaries to studies, unpublished work and study protocols were excluded.

127

128 Data extraction. Data extraction focused on PROMs and clinical outcome measures used to assess pulmonary rehabilitation interventions and that can be easily applied in community-129 130 based practice. Thus, data regarding measures not suitable for this setting (eg, arterial blood gases, cardiopulmonary exercise testing, body plethysmography studies, sputum weight and 131 analysis; penetration index of inhaled radioparticles and hospital length of stay) were not 132 extracted. Data extracted were: outcomes, outcome measures, patient characteristics (ie, age 133 and percentage of predicted forced expiratory volume in 1 second (FEV₁) at stability or in 134 acute exacerbation), treatment setting, time from AECOPD to intervention and duration of 135 intervention. 136

137

138 Phase 2: Properties of Measures

Data sources and searches. A systematic electronic literature search was conducted from
June to July 2016 on PubMed, Web of Science, Scopus, and CINAHL. A validated sensitive
search filter (sensitivity = 97.4%; precision = 4.4%) for finding studies on measurement
properties of outcome measures was used.²⁵ Only outcome measures included in phase 1 were
searched in phase 2, however, if new outcome measures feasible to be used in community
practice emerged from the search, they were also included. Reference lists of the identified

studies were scanned for other potential eligible studies and a weekly update was conducted
until September 2016. The full search strategy can be found in eAppendix 2 (available at:
https://academic.oup.com/ptj).

148

Study selection. Selection of studies was performed by 1 reviewer (A.L.O.) and checked by a 149 second reviewer (A.S.M.). Inclusion and exclusion criteria were as in phase 1. Additionally, 150 studies were included if information was reported regarding 1 or more measurement 151 properties (ie, reliability – internal consistency, reliability, measurement error; validity – 152 content validity, construct validity and criterion validity, responsiveness and interpretability). 153 154 Studies were excluded if reported on measurement properties of outcome measures not feasible to use in community-based pulmonary rehabilitation programs, separated items of an 155 156 outcome measure and did not included the full measure.

157

Data extraction and quality assessment. Data was extracted by 1 reviewer (A.L.O.) using 2
standardized tables, one for PROMs and another for clinical outcome measures. Data
extracted were: outcome, outcome measure, author and year of publication, measurement
property assessed, quality of the study, quality of the measurement property and costs.

Two independent reviewers (A.L.O. and A.S.M.) evaluated the quality of the included studies
using the Consensus-Based Standards for the Selection of Health Status Measurement
Instruments (COSMIN) checklist (ie, poor, fair, good, excellent).²⁶ A consensus method was
used to solve disagreements between reviewers.

The quality of the outcome measures reported was determined using the rating system for 168 measurement properties proposed by Terwee et al.²⁷ For each measurement property a 169 criterion is defined for positive, negative and indeterminate rating. 170 171 Data synthesis and analysis. Data on PROMs and clinical outcome measures were separately 172 analyzed. For each measurement property (ie, reliability, validity, responsiveness and 173 interpretability), a synthesis of the quality of the study, using the COSMIN criteria,²⁶ and of 174 the quality outcome measure, using the system of Terwee et al,²⁷ was performed. 175 176 The consistency of the quality assessment performed by the 2 reviewers was explored with an 177 178 interrater agreement analysis using the Cohen kappa for each box of the COSMIN criteria. The Cohen kappa value ranges from 0 to 1 and can be categorized as slight (< 0.2), fair (0.21– 179 (0.4), moderate (0.41-0.6), substantial (0.61-0.8), or almost perfect (> 0.81) agreement.²⁸ 180 181 Results 182 Phase 1: Measures Used in Pulmonary Rehabilitation 183 Study selection. A total of 220 literature reviews were found. After duplicates were removed 184 (n = 66) and exclusions were made on the basis of abstract and title screenings (n = 22), 132 185 186 full texts were screened and 15 literature reviews that reported on pulmonary rehabilitation interventions in patients with AECOPD were included. Additionally, 24 original studies 187 included in the 15 reviews were extracted and searched for outcome measures not reported in 188 189 the reviews.

The search conducted for original studies published after 2010 retrieved 257 original studies.
After duplicates were removed (n = 134) and exclusions were made on the basis of abstract
and title screenings (n = 23), 100 full texts were screened and 13 original studies were
included. Thus, a total of 37 original studies were searched for outcome measures. A flow
diagram concerning the literature reviews and original studies search and reasons for studies
exclusions can be found in the Figure.

197

Study characteristics. The 37 studies included were conducted in 19 different countries. A steady increase in the number of studies investigating pulmonary rehabilitation in patients with AECOPD was observed, with only 7 papers published from 1964 to 2000 and 37 by 2016. Most studies were randomized control trials $(n = 31)^{15,16,29-57}$ conducted with inpatients (n = 27), $^{15,16,29,30,33,35,37-41,43,45-48,51-61}$ followed by hospital outpatient departments (n = 6), 15,37,38,42,44,49 inpatients plus patients' homes (n = 3), 31,32,50 community settings (n = 3), 34,62,63 and patients' homes $(n = 1)^{36}$ (Tabs. 1 and 2).

Outcomes and outcome measures. Twenty-three PROMs and 18 clinical outcome measures 205 206 were identified. The most common patient-reported outcomes assessed were dyspnea (n = 24), using the modified Borg Scale $(mBorg)^{30,32,38,39,42,44,46,52-55,58,62,63}$ (n = 14), and health-related 207 quality of life (n = 23), using the St George Respiratory Questionnaire $(SGRQ)^{16,34-37,39,42,44,49-1}$ 208 51,54,56,58,59 (n = 15). The most common clinical outcomes assessed were functional exercise 209 capacity (n = 24), using the 6-minute walk test^{16,30-32,37,38,41,43,44,48,49,51-53,56,58,63} (n = 21), and 210 lung function (n = 13), using the $FEV_1^{16,30,31,36,39,44,55,57,60,61}$ (n = 10). Other outcomes assessed 211 were anxiety and depression, fatigue, cough, physical activity, strength, activities of daily 212

213 living, lung function, peripheral blood gases, subjective airway clearance, and body214 composition.

215

Tables 1 and 2 show the patient-reported and clinical outcomes and outcome measuresreported.

218

219 Phase 2: Properties of Measures

Study selection. The search for measurement properties identified 82 studies. After the removal of duplicates, 41 studies were screened. During the title and abstract screening, 18 studies were excluded. The full text of 23 studies was assessed and another 15 studies were excluded. Therefore, 8 original studies were selected. The search for relevant studies within the reference lists retrieved 24 additional studies. Therefore, a total of 32 studies were included in this review (Figure).

226

227 Measurement properties. The measurement properties of 22 PROMs used to assess 5 outcomes (ie, dyspnea [6 outcome measures], health-related quality of life [11 outcome 228 229 measures], health status [2 outcome measures], activities of daily living [2 outcome measures], and general symptoms [1 outcome measure]) were reported by 26 of 32 studies. 230 The measurement properties of 7 clinical outcome measures used to assess 4 outcomes (ie, 231 oxygen saturation [1 outcome measure], lung function [4 outcome measures], body 232 composition [1 outcome measure], and physical activity [1 outcome measure]) were reported 233 in 8 of 32 studies. 234

236	The methodological quality of each study and the quality of the measurement properties of
237	each measure can be found in Tables 3 and 4. The agreement between the 2 independent
238	reviewers using the COSMIN quality assessment was substantial ($\kappa = 0.688$).
239	
240	The characteristics of the included studies and synthesis of the results per outcome and
241	outcome measure can be found in eAppendix 3 (available at: <u>https://academic.oup.com/ptj;</u>
242	eTab. 1a and eTab. 1b).
243	
244	Quality and properties of PROMs. Reliability was studied for 5 PROMs in 5 studies of fair
245	to excellent methodological quality (ie, SGRQ, Chronic Respiratory Diseases Questionnaire
246	[CRQ], Clinical COPD Questionnaire [CCQ], and COPD Assessment Test [CAT]) ^{64–68} and in
247	2 studies of poor methodological quality (ie, CCQ and Exacerbations of Chronic Pulmonary
248	Disease Tool–Patient-Reported Outcome [EXACT-PRO]).67,69 Studies were rated as poor
249	mainly because an analysis of the unidimensionality of the scale was not preformed.
250	
251	Measurement properties presented positive results in all reliability categories assessed (ie,
252	internal consistency and test-retest; measurement error has not been assessed) and for all
253	outcome measures (Tab. 3).
254	
255	Validity was studied for most PROMs, except for the mBorg, visual analog scale, Short-Form
256	6D, and Nottingham Health Profile, in 21 studies. ^{64–84} Overall, the methodological quality of
257	the studies was rated from poor to fair, except for structural validity studied in the CRQ and
258	the CAT, which were rated excellent. ^{64,65} For criterion validity, reasons for rating "poor" were

related with the inadequacy of the gold standard used as comparator. Regarding to construct
validity, weaknesses included lack of formulation of hypotheses and lack of description of the
comparator instrument.

263	Criterion validity was indeterminate in 5 studies (ie, modified Medical Research Council
264	[MRC], MRC, extended MRC, CCQ, COPD severity score, EuroQol 5D [EQ-5D], Breathing
265	Problems Questionnaire, London Chest Activities of Daily Living Scale [LCADL], and
266	Manchester Respiratory Activities of Daily Living Questionnaire) ^{70,71,77,79,81} and positive in 1
267	study (ie, Global Initiative for Chronic Obstructive Lung Disease plus Symptom Severity
268	Index [GOLD + SSI]). ⁸³ Structural validity presented positive results in 2 studies (ie, CRQ
269	and CAT). ^{64,65} Construct validity, was indeterminate in 11 studies (ie, Baseline Dyspnea
270	Index and Transition Dyspnea Index [BDI/TDI], SGRQ, CRQ, CCQ, COPD severity score,
271	EQ-5D, Short-Form 6D, Measure Your Medical Outcome Profile, and Medical Outcomes
272	Study 6-Item General Health Survey, modified MRC, SGRQ, EXACT-PRO, and
273	LCADL) ^{66,68-70,72,75,76,79,80,82} , negative in 2 studies (ie, SGRQ and CRQ) ^{64,73} , and positive in 7
274	studies (ie, SGRQ, CRQ, CCQ, CAT, and Cough and Sputum Assessment
275	Questionnaire) ^{65,67,74-76,78,84} (Tab. 3).

Responsiveness was studied for most PROMs, except for the modified MRC, MRC, extended
MRC, Breathing Problems Questionnaire, GOLD + SSI, Manchester Respiratory Activities of
Daily Living Questionnaire, and LCADL, in 19 studies of poor to fair methodological
quality.^{64,66–69,72–77,79,80,84–89} Common weaknesses of studies included lack of description of the
comparator instrument and inadequacy of design and statistical methods used.

283	Responsiveness was indeterminate in 14 studies (ie, SGRQ, CCQ, COPD severity score, EQ-
284	5D, Short-Form 6D, Nottingham Health Profile, Measure Your Medical Outcome Profile,
285	Medical Outcomes Study 6-Item General Health Survey, EXACT-PRO, Cough and Sputum
286	Assessment Questionnaire, mBorg, visual analog scale, and CCQ), ^{66–69,73,75,77,79,80,84–87,89}
287	negative in 5 studies (ie, SGRQ, CRQ, CAT, and EQ-5D), ^{64,72,74,75,79} and positive in 3 studies
288	(ie, BDI/TDI and CAT) ^{72,76,88} (Tab. 3).
289	
290	Interpretability was found in 2 studies which presented values of the minimal clinically
291	important difference (MCID) for the CRQ (MCID = 1.01) ⁶⁴ and the CCQ (MCID = 0.44). ⁶⁸
292	
293	Quality and properties of clinical measures. Reliability was not studied for any of the
294	clinical outcome measures found (Tab. 4).
295	
296	Validity was studied for all clinical outcome measures in 8 studies of fair to poor
297	methodological quality. ^{70,72,90–95} For criterion validity, reasons for rating "poor" were related
298	with the inadequacy of the gold standard used as comparator, whereas for construct validity
299	reasons were related to the lack of formulation of hypotheses and the lack of description of the
300	comparator instrument.
301	
302	Overall, measurement properties presented positive results for criterion validity assessed in 4
303	studies (ie, peripheral oxygen saturation [SpO2], forced vital capacity, and computerized
304	respiratory sounds) ^{70,90,93,94} ; however, in 1 study assessing the FEV ₁ , criterion validity was
305	indeterminate. ⁷⁰ Regarding to construct validity, indeterminate results were found in 2 studies

306	(ie, SpO ₂ , peak expiratory flow [PEF], FEV ₁ , and forced vital capacity) ^{70,92} and positive
307	results in 3 studies (ie, SpO ₂ , PEF, and time spent in weight-bearing activities assessed with
308	an accelerometer) ^{90,91,95} (Tab. 4).
309	
310	Responsiveness was studied for the PEF and FEV_1 in 2 studies ^{72,91} of fair and poor
311	methodological quality, respectively. The study was rated as poor because it did not describe
312	the measurement properties of the comparator instrument.
313	
314	Responsiveness was rated positive for the PEF^{91} and indeterminate for the FEV_1^{72} (Tab. 4).
315	
316	Interpretability was not studied for any of the clinical outcome measures found (Tab. 4).
317	
318	Discussion
319	To our knowledge, this is the first systematic review to provide a comprehensive overview of
320	the measurement properties of the outcome measures most used in pulmonary rehabilitation
321	programs during AECOPD and that can be easily applied in a community setting. Twenty-

322 three PROMs and 18 clinical outcome measures were identified in intervention studies. The

most used measures were the St George Respiratory Questionnaire (n = 15/37) and the 6-

minute walk test (n = 21/37). Several measures have been used only in isolated studies (ie,

325 New York Heart Association Functional Classification, Activities of Daily Living Dyspnea

326 Scale, diaries, Functional Assessment of Chronic Illness Therapy, feeling thermometer,

327 mBorg fatigue, LCADL, 3-minute step test, 3-minute walk test, 2-minute step-in-place test,

328 FEV₁/forced vital capacity, computerized respiratory sounds, fat-free mass index, body mass

index, accelerometer, quadriceps twitch responses, and maximum inspiratory pressure).
Measurement properties were only synthesized for 22 PROMs and 7 clinical outcome
measures. The methodological quality of most studies was poor, and the results obtained for
the measurement properties were indeterminate. The PROMs and clinical outcome measures
exhibiting the most appropriate measurement properties were the CAT and SpO₂,
respectively.

335

The most used PROMs were the mBorg and the SGRQ. Dyspnea and health-related quality of 336 life have been reported as the outcomes that better reflect the overall impact of the disease⁹⁶ 337 338 and, therefore their monitoring during AECOPD, with appropriate outcome measures, is essential to guide health professionals on the most effective interventions. Nevertheless, the 339 measurement properties of the mBorg have been little reported and, when reported, in studies 340 341 of poor methodological quality. The BDI/TDI, although not commonly used, was the only outcome measure which rated fair and positive for responsiveness on dyspnea. The SGRQ has 342 343 shown appropriate test reliability but inconclusive validity and responsiveness. Although, the SGRQ has strong measurement properties in stable patients with COPD,^{24,97} it 344 reports to the past month, 3 months and 1 year. These inappropriate timeframes to assess 345 346 improvements from an AECOPD, which usually takes 1 to 3 weeks to be meaningful to patients,^{23,98} might explain some of the divergent results found. Measurement properties of 347 CAT have been assessed in a reasonable number of studies of fair methodological 348 quality^{65,75,76,78,88} and positive results have been found. Therefore, the BDI/TDI and CAT may 349 350 be promising PROMs to assess the effectiveness of community-based pulmonary rehabilitation in patients with AECOPD. 351

352

The most used clinical outcome measures were the FEV_1 and the 6-minute walk test. 353 354 However, the measurement properties of the FEV_1 were found in studies of poor methodological quality and no studies were found reporting on the measurement properties of 355 356 the 6-minute walk test in patients with AECOPD which impaired conclusions regarding its use. Similarly to exercise tolerance, no studies were found reporting on measurement 357 358 properties of muscle strength. Currently, it is known that the inflammatory effects of 359 AECOPD are not confined to the lungs but also impair peripheral muscle strength and exercise tolerance.¹ Declines in these outcomes are independent predictors of hospitalizations 360 and mortality.^{99,100} Early rehabilitation may play a crucial role in preventing and reducing 361 losses in exercise capacity, muscle strength and musculoskeletal dysfunction,^{16,43} thus 362 possibly reverting this cascade of events. Nevertheless, there is the urgent need to establish 363 364 the measurement properties of clinical outcome measures for AECOPD to assess patients' 365 dysfunctions, plan interventions, and verify their effectiveness.

366

This systematic review evidenced that the conflicting results of pulmonary rehabilitation 367 programs in patients with AECOPD^{10,15,16,50} may not be related to the quality of treatment but 368 with the lack of appropriateness of measurement proprieties of the outcome measures used. 369 Additionally, whilst the methodology of this review target only measures that could be 370 371 implemented in community settings (ie, simple and accessible measures), our results can also 372 be applicable to other clinical settings where these measures are available. Nevertheless, since most AECOPD are recommended to be managed in the community and community-based 373 374 pulmonary rehabilitation might be a promising intervention for minimizing a patient's decline and prevent recurrence, robust studies on the validity, reliability and responsiveness, as well 375 as on availability, cost and interpretability (ie, by establishing the MCID), of outcome 376

measures are urgently needed. These studies will contribute to clarify the role of community-based pulmonary rehabilitation in patients with AECOPD.

379

380 Study Limitations

This study has some limitations that need to be acknowledged. Several relevant studies for 381 this systematic review^{67–69,71–73,75,77–79,81–83,85,86,88–95} were not found with the validated search 382 strategy used and were only included after searching through the reference lists of the 383 reviewed studies. Relevant studies may have fallen out of the search due the absence of 384 keywords related to measurement properties in their title, abstract or keywords, which 385 impaired the filter used to identify them. Adequate use of the Medical Subject Headings 386 (MESH) terms is warranted to identify the purpose of the studies and improve the quality of 387 the results found in future systematic reviews. 388

389

This systematic review has followed the COSMIN recommendations to assess the quality of the included studies. The COSMIN was originally developed for health-related PROMs, such as questionnaires,²⁶ and thus its validity, reliability and adequacy for assessing the methodological quality of clinical studies and outcome measures, may be questioned. Nonetheless, in the absence of a measure specifically designed to evaluate such studies and outcome measures, the COSMIN is indicated as an adequate alternative tool.^{101,102}

396

The selection of studies was performed by 1 reviewer which could have caused bias in the
studies selection. This limitation has been mitigated by consulting a second reviewer when
uncertainties were found and by defining strict inclusion and exclusion criteria prior to studies
selection.

401

402	Finally, 3 of the studies included presented combined results of stable and exacerbated
403	patients with COPD ^{69,73,74} which could have affected some of the conclusions established.
404	Nevertheless, the results of these studies have been considered within the universe of all
405	studies included, and thus we believe that any potential bias that could have been introduced
406	was diluted. Future studies should focus on patients with AECOPD only, so that
407	recommendations regarding its measurement properties can be established with confidence.

408

409 Conclusions

410 Although a large number of outcome measures easy to implement in a community-based 411 setting have been used to assess pulmonary rehabilitation in patients with AECOPD, their measurement properties have been poorly studied. Given the wide availability of measures it 412 does not seem necessary to develop new outcome measures to be used in community-based 413 414 pulmonary rehabilitation of patients with AECOPD. Instead, studies following the COSMIN standards to evaluate the measurement properties (ie, reliability, validity and responsiveness) 415 of the existing outcome measures are recommended. Such studies would contribute to clarify 416 417 the role of community-based pulmonary rehabilitation in patients with AECOPD and guide the development of core outcome sets. 418

420 Author Contributions

- 421 Concept/idea/research design: A.L. Oliveira, A.S. Marques
- 422 Writing: A.L. Oliveira, A.S. Marques
- 423 Data collection: A.L. Oliveira
- 424 Data analysis: A.L. Oliveira
- 425 Project management: A.L. Oliveira
- 426 Fund procurement: A.L. Oliveira
- 427 Providing facilities/equipment: A.S. Marques
- 428 Providing institutional liaisons: A.S. Marques
- 429 Consultation (including review of manuscript before submitting): A.L. Oliveira, A.S. Marques
- 430
- 431 Funding
- 432 This work was partially supported by Fundo Europeu de Desenvolvimento Regional (FEDER)
- 433 through Programa Operacional Competitividade e Internacionalização (COMPETE) and
- 434 Fundação para a Ciência e Tecnologia (FCT) under projectsUID/BIM/04501/2013 and
- 435 SFRH/BD/101951/2014. The funders had no role in the conduct of this review.
- 436

437 Disclosures

438 The authors completed the ICJME Form for Disclosure of Potential Conflicts of Interest. No

disclosures were reported.

441

References

- 1. Anzueto A. Impact of exacerbations on COPD. *Eur Respir Rev.* 2010;19:113–118.
- The Global Initiative for Chronic Obstructive Lung Disease. *Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease:*2017 Report. The Global Initiative for Chronic Obstructive Lung Disease, Inc; 2017.
- Cambach W, Chadwick-Straver R, Wagenaar R, Van Keimpema A, Kemper H. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. *Eur Respir J.* 1997;10:104–113.
- 4. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 2006;(4):CD003793.
- 452 5. Neves LF, Reis MH, Gonçalves TR. Home or community-based pulmonary
 453 rehabilitation for individuals with chronic obstructive pulmonary disease: a systematic
 454 review and meta-analysis. *Cad Saúde Pública*. 2016;32:1–25.
- 6. Cecins N, Landers H, Jenkins S. Community-based pulmonary rehabilitation in a nonhealthcare facility is feasible and effective. *Chron Respir Dis.* 2017;14:3–10.
- 457 7. Holland AE. Physiotherapy management of acute exacerbations of chronic obstructive
 458 pulmonary disease. *J Physiother*. 2014;60:181–188.
- 459 8. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of
 460 chronic obstructive pulmonary disease in the USA. *Clinicoecon Outcomes Res.*461 2013;5:235–245.
- 462 9. Xie X, Schaink A, Wang M, Krahn M. Pulmonary Rehabilitation for Postacute
 463 Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost464 effectiveness and Budget Impact Analysis. Toronto, Ontario, Canada: Queen's Printer
 465 for Ontario; 2015.
- Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J.
 Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary
 disease. *Cochrane Database Syst Rev.* 2016;(12):CD005305.
- Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a
 European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*.
 2017;49:1600791.
- 472 12. Jones SE, Green SA, Clark AL, et al. Pulmonary rehabilitation following hospitalisation for acute exacerbation of COPD: referrals, uptake and adherence.
 474 *Thorax.* 2014;68:181–182.
- 475 13. De Vet HCW, Terwee CB, Mokkink LB, Knol DL. *Measurement in Medicine:*476 *Practical Guide to Biostatistics and Epidemiology*. London, England: Cambridge
 477 University Press; 2011.
- 478 14. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2006;3:245–251.
- Puhan MA, Spaar A, Frey M, et al. Early versus late pulmonary rehabilitation in chronic obstructive pulmonary disease patients with acute exacerbations: a randomized trial. *Respiration*. 2012;83:499–506.
- 483 16. Borges RC, Carvalho CR. Impact of resistance training in chronic obstructive
 484 pulmonary disease patients during periods of acute exacerbation. *Arch Phys Med*485 *Rehabil.* 2014;95:1638–1645.
- Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory
 Society/American Thoracic Society technical standard: field walking tests in chronic
 respiratory disease. *Eur Respir J*. 2014;44:1428–1446.

- 489 18. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. *Chest.* 2001;119:1190–1209.
- Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. *Chron Respir Dis.* 2010;7:9–17.
- 494 20. Tang CY, Taylor NF, Blackstock FC. Chest physiotherapy for patients admitted to
 495 hospital with an acute exacerbation of chronic obstructive pulmonary disease (COPD):
 496 a systematic review. *Physiotherapy*. 2010;96:1–13.
- 497 21. Osadnik CR, McDonald CF, Jones AP, Holland AE. Airway clearance techniques for 498 chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* 499 2012;(3):CD008328.
- Björk B-C, Solomon D. The publishing delay in scholarly peer-reviewed journals. J
 Informetr. 2013;7:914–923.
- Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course
 and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2000;161:1608–1613.
- 505 24. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic
 506 Society/European Respiratory Society statement: key concepts and advances in
 507 pulmonary rehabilitation. *Am J Respir Crit Care Med.* 2013;188:e13–e64.
- 508 25. Terwee CB, Jansma EP, Riphagen II, de Vet HCW. Development of a methodological
 509 PubMed search filter for finding studies on measurement properties of measurement
 510 instruments. *Qual Life Res.* 2009;18:1115–1123.
- 511 26. Terwee CB, Mokkink LB, Knol DL, Ostelo RWJG, Bouter LM, de Vet HCW. Rating
 512 the methodological quality in systematic reviews of studies on measurement
 513 properties: a scoring system for the COSMIN checklist. *Qual Life Res.* 2012;21:651–
 514 657.
- 515 27. Terwee CB, Bot SD, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol*. 2007;60:34–
 517 42.
- 518 28. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
 519 *Biometrics*. 1977;33:159–174.
- Petersen ES, Esmann V, Honcke P, Munkner C. A controlled study of the effect of
 treatment on chronic bronchitis: an evaluation using pulmonary function tests. *Acta Med Scand.* 1967;182:293–305.
- 523 30. Kirsten DK, Taube C, Lehnigk B, Jorres RA, Magnussen H. Exercise training
 524 improves recovery in patients with COPD after an acute exacerbation. *Respir Med.*525 1998;92:1191–1198.
- 31. Behnke M, Taube C, Kirsten D, Lehnigk B, Jorres RA, Magnussen H. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. *Respir Med.* 2000;94:1184–1191.
- 32. Behnke M, Jörres RA, Kirsten D, Magnussen H. Clinical benefits of a combined hospital and home-based exercise programme over 18 months in patients with severe COPD. *Monaldi Arch Chest Dis.* 2003;59:44–51.
- 33. Yohannes AM, Connolly MJ. Early mobilization with walking aids following hospital
 admission with acute exacerbation of chronic obstructive pulmonary disease. *Clin Rehabil.* 2003;17:465–471.
- Man WD, Polkey MI, Donaldson N, Gray BJ, Moxham J. Community pulmonary
 rehabilitation after hospitalisation for acute exacerbations of chronic obstructive
 pulmonary disease: randomised controlled study.*BMJ*. 2004;329:1209.

- 538 35. Basoglu OK, Atasever A, Bacakoglu F. The efficacy of incentive spirometry in patients with COPD. *Respirology*. 2005;10:349–353.
- Murphy N, Bell C, Costello RW. Extending a home from hospital care programme for
 COPD exacerbations to include pulmonary rehabilitation. *Respir Med.* 2005;99:1297–
 1302.
- 543 37. Carr SJ, Hill K, Brooks D, Goldstein RS. Pulmonary rehabilitation after acute
 544 exacerbation of chronic obstructive pulmonary disease in patients who previously
 545 completed a pulmonary rehabilitation program. *J Cardiopulm Rehabil Prev.*546 2009;29:318–324.
- 547 38. Eaton T, Young P, Fergusson W, et al. Does early pulmonary rehabilitation reduce
 548 acute health-care utilization in COPD patients admitted with an exacerbation? A
 549 randomized controlled study. *Respirology*. 2009;14:230–238.
- Kodric M, Garuti G, Colomban M, et al. The effectiveness of a bronchial drainage
 technique (ELTGOL) in COPD exacerbations. *Respirology*. 2009;14:424–428.
- 40. Aggarwal RR, Shaphe A, George C, Vats A. A comparison of flutter device and active cycle of breathing techniques in acute exacerbation of chronic obstructive pulmonary disease patients. *Indian J Physiother Occup Ther*. 2010;4:60–64.
- Babu AS, Noone MS, Haneef M, Samuel P. The effects of 'on-call/out of hours' physical therapy in acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Clin Rehabil.* 2010;24:802–809.
- Seymour JM, Moore L, Jolley CJ, et al. Outpatient pulmonary rehabilitation following
 acute exacerbations of COPD. *Thorax.* 2010;65:423–428.
- 43. Troosters T, Probst VS, Crul T, et al. Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2010;181:1072–1077.
- Ko FWS, Dai DLK, Ngai J, et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. *Respirology*. 2011;16:617–624.
- 45. Giavedoni S, Deans A, McCaughey P, Drost E, MacNee W, Rabinovich RA.
 Neuromuscular electrical stimulation prevents muscle function deterioration in exacerbated COPD: a pilot study. *Respir Med.* 2012;106:1429–1434.
- 569 46. Sonia, Gupta C. Effect of Acu-TENS on pulmonary functions in patients with acute
 570 exacerbation of chronic obstructive pulmonary disease. *Indian J Physiother Occup*571 *Ther.* 2012;6:115–119.
- 572 47. Chaplin EJL, Houchen L, Greening NJ, et al. Neuromuscular stimulation of quadriceps in patients hospitalised during an exacerbation of COPD: a comparison of low (35 Hz) and high (50 Hz) frequencies. *Physiother Res Int.* 2013;18:148–156.
- Goktalay T, Akdemir SE, Alpaydin AO, Coskun AS, Celik P, Yorgancioglu A. Does
 high-frequency chest wall oscillation therapy have any impact on the infective
 exacerbations of chronic obstructive pulmonary disease? A randomized controlled
 single-blind study. *Clin Rehabil.* 2013;27:710–718.
- 579 49. Deepak TH, Mohapatra PR, Janmeja AK, Sood P, Gupta M. Outcome of pulmonary
 580 rehabilitation in patients after acute exacerbation of chronic obstructive pulmonary
 581 disease. *Indian J Chest Dis Allied Sci.* 2014;56:7–12.
- 582 50. Greening NJ, Williams JEA, Hussain SF, et al. An early rehabilitation intervention to
 583 enhance recovery during hospital admission for an exacerbation of chronic respiratory
 584 disease: randomised controlled trial.*BMJ*. 2014;349:g4315.
- 585 51. Osadnik CR, McDonald CF, Miller BR, et al. The effect of positive expiratory 586 pressure (PEP) therapy on symptoms, quality of life and incidence of re-exacerbation

in patients with acute exacerbations of chronic obstructive pulmonary disease: a
multicentre, randomised controlled trial. *Thorax.* 2014;69:137–143.

- 589 52. He M, Yu S, Wang L, Lv H, Qiu Z. Efficiency and safety of pulmonary rehabilitation
 590 in acute exacerbation of chronic obstructive pulmonary disease. *Med Sci Monit.*591 2015;21:806–812.
- 53. Liao L-Y, Chen K-M, Chung W-S, Chien J-Y. Efficacy of a respiratory rehabilitation exercise training package in hospitalized elderly patients with acute exacerbation of COPD: a randomized control trial. *Int J Chron Obstruct Pulmon Dis.* 2015;10:1703–1709.
- 54. Martín-Salvador A, Colodro-Amores G, Torres-Sánchez I, Moreno-Ramírez MP,
 Cabrera-Martos I, Valenza MC. Intervención fisioterápica durante la hospitalización
 en pacientes con exacerbación aguda de la enfermedad pulmonar obstructiva crónica y
 neumonía: un ensayo clínico aleatorizado. *Med Clin (Barc)*. 2016;146:301–304.
- 55. Torres-Sanchez I, Valenza MC, Saez-Roca G, Cabrera-Martos I, Lopez-Torres I,
 Rodriguez-Torres J. Results of a multimodal program during hospitalization in obese
 COPD exacerbated patients. *COPD*. 2016;13:19–25.
- 56. Cross JL, Elender F, Barton G, et al. Evaluation of the effectiveness of manual chest
 physiotherapy techniques on quality of life at six months post exacerbation of COPD
 (MATREX): a randomised controlled equivalence trial. *BMC Pulm Med.* 2012;12:33.
- 57. Tang CY, Blackstock FC, Clarence M, Taylor NF. Early rehabilitation exercise
 program for inpatients during an acute exacerbation of chronic obstructive pulmonary
 disease: a randomized controlled trial. *J Cardiopulm Rehabil Prev.* 2012;32:163–169.
- 609 58. Clini EM, Crisafulli E, Costi S, et al. Effects of early inpatient rehabilitation after
 610 acute exacerbation of COPD. *Respir Med.* 2009;103:1526–1531.
- 59. Meglic U, Sorli J, Kosnik M, Lainscak M. Feasibility of transcutaneous electrical muscle stimulation in acute exacerbation of COPD. *Wien Klin Wochenschr*.
 613 2011;123:384–387.
- 614 60. Ngai SP, Jones AY, Hui-Chan CW, Ko FW, Hui DS. An adjunct intervention for
 615 management of acute exacerbation of chronic obstructive pulmonary disease
 616 (AECOPD). J Altern Complement Med. 2013;19:178–181.
- 617 61. Eastwood B, Jepsen N, Coulter K, Wong C,Zeng I. Challenges of undertaking a
 618 clinical trial using bubble-PEP in an acute exacerbation of chronic obstructive
 619 pulmonary disease: a feasibility study. NZJ Physiother. 2016;44:8–16.
- 620 62. Oliveira A, Pinho C, Marques A. Effects of a respiratory physiotherapy session in patients with LRTI: a pre/post-test study. *Clin Respir J.* 2017;11:703–712.
- 622 63. Oliveira A, Marques A. Exploratory mixed methods study of respiratory physiotherapy for patients with lower respiratory tract infections. *Physiotherapy*.
 624 2016;102:111–118.
- 625 64. Tsai CL, Hodder RV, Page JH, Cydulka RK, Rowe BH, Camargo CA Jr. The Short626 Form Chronic Respiratory Disease Questionnaire was a valid, reliable, and responsive
 627 quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary
 628 disease. J Clin Epidemiol. 2008;61:489–497.
- 629 65. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development
 630 and first validation of the COPD Assessment Test. *Eur Respir J.* 2009;34:648–654.
- 631 66. Katsoulas TA, Skordilis EK, Myrianthefs P, Fildisis G, Theodosopoulou E,
 632 Baltopoulos G. Validity of St. George's Respiratory Questionnaire for Greek patients
 633 with chronic obstructive pulmonary disease. *Percept Mot Skills*. 2010;110:772–788.
- 634 67. Antoniu SA, Puiu A, Zaharia B, Azoicai D. Health status during hospitalisations for
 635 chronic obstructive pulmonary disease exacerbations: the validity of the Clinical
 636 COPD Questionnaire. *Expert Rev Pharmacoecon Outcomes Res.* 2014;14:283–287.

- 637 68. Kocks JWH, Tuinenga MG, Uil SM, van den Berg JWK, Ståhl E, van der Molen T.
 638 Health status measurement in COPD: the minimal clinically important difference of
 639 the Clinical COPD Questionnaire. *Respir Res.* 2006;7:1–8.
- 640 69. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing
 641 measurement of chronic obstructive pulmonary disease exacerbations: reliability and
 642 validity of a patient-reported diary. *Am J Respir Crit Care Med.* 2011;183:323–329.
- 643 70. Güryay MS, Ceylan E, Günay T, et al. Can spirometry, pulse oximetry and dyspnea
 644 scoring reflect respiratory failure in patients with chronic obstructive pulmonary
 645 disease exacerbation? *Med Princ Pract.* 2007;16:378–383.
- 546 71. Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC. Dyspnoea severity and
 pneumonia as predictors of in-hospital mortality and early readmission in acute
 exacerbations of COPD. *Thorax.* 2012;67:117–121.
- Aaron SD, Vandemheen KL, Clinch JJ, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. *Chest.* 2002;121:688–696.
- Doll H, Duprat-Lomon I, Ammerman E, Sagnier PP. Validity of the St George's Respiratory Questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham Health Profile. *Qual Life Res.* 2003;12:117–132.
- 655 74. Bourbeau J, Maltais F, Rouleau M, Guimont C. French-Canadian version of the
 656 Chronic Respiratory and St George's Respiratory questionnaires: an assessment of
 657 their psychometric properties in patients with chronic obstructive pulmonary disease.
 658 *Can Respir J.* 2004;11:480–486.
- Jones PW, Harding G, Wiklund I, et al. Tests of the responsiveness of the COPD
 Assessment Test following acute exacerbation and pulmonary rehabilitation. *Chest.*2012;142:134–140.
- Tu YH, Zhang Y, Fei GH. Utility of the CAT in the therapy assessment of COPD exacerbations in China. *BMC Pulm Med.* 2014;14:1–8.
- Trappenburg JC, Touwen I, de Weert-van Oene GH, et al. Detecting exacerbations
 using the Clinical COPD Questionnaire. *Health Qual Life Outcomes*. 2010;8:1–9.
- For a cross-sectional European study. *Eur Respir J.* 2011;38:29–35.
- Miravitles M, Izquierdo I, Herrejón Á, Torres JV, Baró E, Borja J. COPD severity
 score as a predictor of failure in exacerbations of COPD: the ESFERA study. *Respir Med.* 2011;105:740–747.
- 80. Paterson C, Langan CE, McKaig GA, et al. Assessing patient outcomes in acute
 exacerbations of chronic bronchitis: the Measure Your Medical Outcome Profile
 (MYMOP), Medical Outcomes Study 6-Item General Health Survey (MOS-6A) and
 EuroQol (EQ-5D). *Qual Life Res.* 2000;9:521–527.
- 81. Yohannes AM, Baldwin RC, Connolly MJ. Predictors of 1-year mortality in patients discharged from hospital following acute exacerbation of chronic obstructive pulmonary disease. *Age Ageing*. 2005;34:491–496.
- 82. Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of
 Chronic Pulmonary Disease Tool patient-reported outcome measure in three clinical
 trials of chronic obstructive pulmonary disease. *Ann Am Thorac Soc.* 2014;11:316–
 325.
- 83. Hutchinson AF, Thompson MA, Brand CA, Black J, Anderson GP, Irving LB.
 Community care assessment of exacerbations of chronic obstructive pulmonary
 disease. J Adv Nurs. 2010;66:2490–2499.

- 685 84. Monz BU, Sachs P, McDonald J, Crawford B, Nivens MC, Tetzlaff K.
 686 Responsiveness of the Cough and Sputum Assessment Questionnaire in exacerbations
 687 of COPD and chronic bronchitis. *Respir Med.* 2010;104:534–541.
- Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg Scale in assessing the degree of dyspnea in patients with COPD and asthma. *J Emerg Nurs.*2000;26:216.
- 691 86. Lemasson S, Nesme P, Herblanc A, et al. Changes in inspiratory capacity during acute
 692 respiratory failure in COPD patients [in French]. *Rev Mal Respir*. 2007;24:314–322.
- 693 87. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe
 694 COPD hospitalized for exacerbations: comparing EQ-5D, SF-12 and SGRQ. *Health*695 *Qual Life Outcomes*. 2010;8:1–9.
- Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness
 of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of
 COPD exacerbations. *Am J Respir Crit Care Med.* 2012;185:1218–1224.
- 699 89. Goossens LMA, Nivens MC, Sachs P, Monz BU, Rutten-Van Mölken MPMH. Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? *Respir Med.* 2011;105:1195–1202.
- 702 90. Kelly AM, McAlpine R, Kyle E. How accurate are pulse oximeters in patients with acute exacerbations of chronic obstructive airways disease? *Respir Med.* 2001;95:336–340.
- P1. Emerman CL, Cydulka RK. Use of peak expiratory flow rate in emergency department
 evaluation of acute exacerbation of chronic obstructive pulmonary disease. *Ann Emerg Med.* 1996;27:159–163.
- White AJ, O'Brien C, Hill SL, Stockley RA. Exacerbations of COPD diagnosed in primary care: changes in spirometry and relationship to symptoms. *COPD*. 2005;2:419–425.
- Morillo DS, León Jiménez A, Moreno SA. Computer-aided diagnosis of pneumonia in patients with chronic obstructive pulmonary disease. *J Am Med Inform Assoc*. 2013;20(e1):e111–e117.
- 714 94. Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C, Kotanidou A.
 715 Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J
 716 Gen Intern Med. 2009;24:1043–1048.
- Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. *Chest.* 2006;129:536–544.
- Janson C, Marks G, Buist S, et al. The impact of COPD on health status: findings from the BOLD study. *Eur Respir J.* 2013;42:1472–1483.
- 97. Weldam SW, Schuurmans MJ, Liu R, Lammers JW. Evaluation of quality of life
 instruments for use in COPD care and research: a systematic review. *Int J Nurs Stud.*2013;50:688–707.
- Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower
 respiratory tract infections: full version. *Clin Microbiol Infect*. 2011;17(suppl 6):E1–
 E59.
- Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic
 Society/European Respiratory Society statement: update on limb muscle dysfunction
 in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2014;189:e15–
 e62.
- Neder JA, Alharbi A, Berton DC, et al. Exercise ventilatory inefficiency adds to lung
 function in predicting mortality in COPD. *COPD*. 2016;13:416–424.

- 101. Bartels B, de Groot JF, Terwee CB. The six-minute walk test in chronic pediatric conditions: a systematic review of measurement properties. *Phys Ther.* 2013;93:529–541.
- 102. Dobson F, Hinman RS, Hall M, Terwee CB, Roos EM, Bennell KL. Measurement
 properties of performance-based measures to assess physical function in hip and knee
 osteoarthritis: a systematic review. *Osteoarthritis Cartilage*. 2012;20:1548–1562.

739 **Table 1.**

740 Patient-Reported Outcomes Used in Pulmonary Rehabilitation of Patients With Acute Exacerbation (AE) of Chronic Obstructive Pulmonary

741 Disease $(COPD)^a$

Outcome	Outcome Measure	Patient C	Characte	ristics		Intervention Setting	Intervention Timing	Intervention Duration	
		No. of Patients	Age (y)	FEV1pp (%)	FEV1ppAE (%)	FEV1ppST (%)	being	1	Duration
Dyspnea	BDI/TDI ^{30–32}	26–30	62.3– 69		34.1–60		Inpatient and home	4–8 d after hospital presentation	11 d–18 mo
	VAS ^{35,60}	1–27	68.4– 74	NS			Inpatient	At hospital presentation to 2 d after hospital presentation	45 min–2 mo
	Borg Scale ^{33,36,41}	26–110	61–75			35–42	Inpatient and home	At hospital presentation to hospital discharge	Until hospital discharge to 6 wk
	mBorg ^{30,32,38,39,42,44,46,52–} 55,58,62,63	19– 1,826	45– 78.8		34.1–69.4	50.5–56	Inpatient, hospital outpatient department, and	At hospital presentation to 3 wk after discharge	60 min–19 mo

							community		
	MRC ^{36,39,49,52,59}	19–94	58.4– 73.9		38–53.3	29–56	Inpatient, hospital outpatient department, and home	At hospital presentation to 2 wk after discharge	Until hospital discharge to 12 wk
	mMRC ^{15,38,44,48,51,63}	19–97	56.8– 73.8 (mean)		35–69.4	37.3–44.4	Inpatient, hospital outpatient department, and community	At hospital presentation to 3 wk after discharge	Until hospital discharge to 12 wk
	NYHA ⁴¹	38	61	NS			Inpatient	As soon as stable	Until hospital discharge
	ADLDS ⁵²	94	69.2– 73.9		38–39		Inpatient	2 d after hospital presentation	Until hospital discharge
HRQL	Diary ³²	26	64–69		34.9–37.5		Inpatient and home	4–7 d after admission	19 mo
	CRQ ^{15,31,32,34,37,38,42,52}	19–97	64– 73.9		34.1–52	36.7–42.7	Inpatient, hospital outpatient department, community, and home	As soon as stable to 3.7 wk after hospital presentation	Until hospital discharge to 18 mo

SGRQ ^{16,34–37,39,42,44,49–} 51,54,56,58,59	19– 1,826	58.4– 78.8	35.6–56.1	29–56	Inpatient, hospital outpatient department, community, and home	As soon as stable to 2 wk after hospital presentation	Until hospital discharge to 12 wk
SF-36 ^{34,38,44}	24–97	69.6– 73.8	35–56.1	36.7–41.7	Inpatient, hospital outpatient department, and community	After discharge to 3 wk after hospital presentation	8 wk
EQ-5D ^{36,42,55,56}	16–526	65– 73.7	52	38-42	Inpatient, hospital outpatient department, and home	As soon as stable to 1 wk after hospital discharge	Until hospital discharge to 8 wk
CAT ^{52,61}	11–94	69.2– 78	34–39		Inpatient	1–2 days after hospital presentation	2 d to until hospital discharge
FACIT fatigue ⁵⁹	19	71		29	Inpatient	Immediately at hospital presentation	6 wk
Feeling thermometer ¹⁵	19	67.5		42.7	Inpatient or hospital outpatient department	2 wk after hospital presentation	12 wk

Anxiety and depression	HADS ^{38,55}	49–97	69.7– 73.7	35–41			Inpatient and hospital outpatient department	As soon as stable to immediately after discharge	Until hospital discharge to 8 wk
Fatigue	mBorg ⁴²	60	65–67	52			Hospital outpatient department	1 wk after discharge	8 wk
Sputum	VAS sputum ^{53,61}	11–61	68–78		34–39		Inpatient	As soon as stable	2–4 d
General symptoms	BCSS ^{51,56,61,62}	11–90	56.8– 78		34–69.4	37.3–44.4	Inpatient and community	At hospital presentation to 72 h after hospital presentation	60 min to until hospital discharge
ADL	Barthel Index ^{33,57}	21–110	68–75		45.1-46.1	35–38	Inpatient	At hospital presentation to 72 h after hospital presentation	Until hospital discharge
	LCADL ⁵⁴	44	77.4– 78.8		41.8-41.4		Inpatient	As soon as stable	8–9 d
Composite measure	BODE Index ^{38,48,51,52}	50–97	65.1– 73.9		35–39	37.3-44.4	Inpatient and hospital outpatient department	At hospital presentation to 2 d after hospital presentation	Until hospital discharge to 8 wk

 a ADL = activities of daily living; ADLDS = Activity of Daily Living Dyspnea Scale; AE = acute exacerbation; BCSS = Breathlessness, Cough,

- and Sputum Scale; BDI/TDI = Baseline Dyspnea Index and Transition Dyspnea Index; BODE = body mass index, airflow obstruction, dyspnea,
- and exercise capacity; CAT = COPD Assessment Test; CRQ = Chronic Respiratory Disease Questionnaire; EQ-5D = EuroQol 5D; FACIT =
- Functional Assessment of Chronic Illness Therapy; FEV₁pp = percentage predicted forced expiratory volume in 1 s; HADS = Hospital Anxiety
- and Depression Scale; HRQL = Health-Related Quality of Life; LCADL = London Chest Activities of Daily Living Scale; mBorg = modified
- ⁷⁴⁷Borg Scale; MRC = Medical Research Council; mMRC = modified MRC; NS = not stated; NYHA = New York Heart Association Functional
- 748 Classification; SF-36 = Short Form (36-Item) Health Survey; SGRQ = St George Respiratory Questionnaire; ST = stable; VAS = visual analog 749 scale.
- 749 750

Table 2.

Clinical Outcomes Used in Pulmonary Rehabilitation of Patients With Acute Exacerbation (AE) of Chronic Obstructive Pulmonary Disease
 (COPD)^a

Outcome	Outcome Measure	Patient (Charact	eristics			Interventio n Setting	Interventio n Timing	Interventio n Duration
		No. of Patient s	Age (y)	FEV1p p	FEV1ppA E	FEV1ppS T	n Setting		
Functional exercise capacity	6MWT ^{16,30–} 32,37,38,41,43,44,48,49,51– 53,56,58,63	28– 1,826	61– 73.9		34.1–69.4	50.5	Inpatient, hospital outpatient department, community, and home	At hospital presentation to 3 wk after discharge	4 d–18 mo
	ISWT ^{34,36,42,50}	26–196	65– 71.1		52	36.7–51.9	Inpatient, hospital outpatient department, community, and home	Immediately to 10 d after discharge	6–8 wk
	ESWT ^{42,47,50}	20–196	65– 70.1		52	39.8–51.9	Inpatient, hospital outpatient department, and home	At hospital presentation to 1 wk after discharge	Until hospital discharge to 8 wk

	3-min step test ³⁶	26	65– 67		38–42	Home	Immediately after discharge	6 wk
	3-min walk test ⁵⁷	21	68– 73.6	45.1–46.1		Inpatient	48 h after hospital presentation	Until hospital discharge
	2-minute step-in-place test ⁵⁵	49	72.4 - 73.7	39–41		Inpatient	As soon as stable	Until hospital discharge
Oxygen saturation	SpO ₂ ^{30,38–40,52,55,56,60,62}	1–526	56.8 - 73.9	35–69.4	52–56	Inpatient, hospital outpatient department, and community	At hospital presentation to 8 d after hospital presentation	45 min–8 wk
Lung function	FEV1 ^{16,30,31,36,39,44,55,57,60,61}	1-60	62.3 -78	34–56.1	38–56	Inpatient, hospital outpatient department, and home	At hospital presentation to 3 wk after hospital discharge	45 min–18 mo
	FVC ^{30,31,36,39,61}	11–59	62.3 -78	34–39	38–56	Inpatient and home	At hospital presentation to immediately after hospital discharge	2 d–18 mo

	FEV ₁ /FVC ³⁹	59	70.2			57.9–64.4	Inpatient	At hospital presentation	7 d
	PEF ^{40,41}	38-45	61	NS			Inpatient	At hospital presentation	Until hospital discharge
	CRS ⁶²	19	56.8		69.4		Community	Within 48 to 72 h after hospital presentation	3 wk
Body compositio n	Fat-free mass index ⁴²	60	65– 67		52		Hospital outpatient department	1 wk after hospital discharge	8 wk
	BMI ⁵¹	90	67.8 - 69.5		35.9–35.6	37.3-44.4	Inpatient	2 d after hospital presentation	Until hospital discharge
Physical activity	Accelerometer ¹⁶	29	67.8 - 64.1		39.1-41.7		Inpatient	3 d after hospital presentation	At least 3 sessions
Strength	MVIC ^{16,36,42,43,45,47,50,54,55,5} 7	11–196	65– 78.8		39.1–52	38–51.9	Inpatient, hospital outpatient department, and home	At hospital presentation to 1 wk after hospital discharge	7 d–8 wk
	TwQ ⁴²	60	65– 67		52		Hospital outpatient	1 wk after hospital	8 wk

				department	discharge	
MIP ³⁰	28	62.3 - 65.6	38	Inpatient	6–8 d after hospital presentation	11 d

 a 6MWT = 6-min walk test; AE = acute exacerbation; BMI = body mass index; CRS = computerized respiratory sounds; ESWT = endurance

shuttle walk test; FEV_1 = forced expiratory volume in 1 s; FEV_1pp = percentage predicted FEV_1 ; FVC = forced vital capacity; ISWT =

incremental shuttle walk test; MIP = maximum inspiratory pressure; MVIC = maximal voluntary isometric contraction; NS = not stated; PEF =

peak expiratory flow; SpO_2 = peripheral oxygen saturation; ST = stable; TwQ = quadriceps twitch responses.

760 **Table 3.**

- 761 Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement
- 762 Property, and Cost of Patient-Reported Outcomes^a

Outcome	Outcome	Study	Reliabi	lity		Validit	Responsive	Cost	
	Measure		Internal Consisten cy	Test- Rete st	Criterio n Validity	Structur al Validity	Construct Validity (Hypothesis Testing)	ness	
Dyspnea	mBorg	Kendrick et al, 2000 ⁸⁵						Poor/?	Free
	VAS	Lemasson et al, 2007 ⁸⁶						Poor/?	Free
	mMRC	Güryay et al, 2007 ⁷⁰			Poor/?		Poor/?		Free
	MRC	Steer et al, 2012 ⁷¹			Poor/?				Free
	eMRC	Steer et al, 2012 ⁷¹			Poor/?				No information
	BDI/TDI	Aaron et al, 2002 ⁷²					Poor/?	Fair/+	Not free for commercial use
HRQL	SGRQ	Doll et al, 2003 ⁷³					Fair/-	Poor/?	Free
		Bourbeau et al, 2004 ⁷⁴					Fair/+	Fair/-	
		Menn et al, 2010 ⁸⁷						Poor/?	
		Katsoulas et al, 2010 ⁶⁶		Fair/+			Good/?	Poor/?	
		Jones et al, 2012 ⁷⁵					Poor/?	Poor/?	
		Tu et al, 2014 ⁷⁶					Poor/?		
	CRQ	Bourbeau et al, 2004 ⁷⁴					Fair/+	Fair/-	Not free
		Tsai et al,	Excellent/+			Excellent/	Poor/-	Fair/-	

	200864				+			
	Aaron et al, 2002 ⁷²					Poor/?	Fair/-	
CCQ	Trappenburg et al,2010 ⁷⁷			Fair/?			Poor/?	Not free
	Antoniu et al, 2014 ⁶⁷	Poor/+	Fair/+			Fair/+	Poor/?	
	Kocks et al, 2006 ⁶⁸					Poor/?	Poor/?	
CAT	Jones et al, 2009 ⁶⁵	Excellent/+			Excellent/ +	Fair/+		Not free for commercial
	Jones et al, 2011 ⁷⁸					Fair/+		use
	Jones et al 2012 ⁷⁵					Fair/+	Poor/-	
	Mackay et al, 2012 ⁸⁸						Fair/+	
	Tu et al, 2014 ⁷⁶					Poor/+	Fair/+	
COPDSS	Miravitlles et al, 2011 ⁷⁹			Fair/?		Poor/?	Poor/?	Free
EQ-5D	Menn et al, 2010 ⁸⁷						Poor/?	Not free for clinical and
	Goossens et al, 2011 ⁸⁹						Poor/?	commercial use
	Miravitlles et al, 2011 ⁷⁹			Fair/?		Poor/?	Fair/-	
	Paterson et al, 2000 ⁸⁰					Poor/?	Poor/?	
SF-6D	Menn et al, 2010 ⁸⁷						Poor/?	Not free for commercial use
BPQ	Yohannes et al, 2005 ⁸¹			Poor/?				Not free for commercial use
NHP	Doll et al, 2003 ⁷³						Poor/?	Not free; copyright held by Galen Research
MYMOP	Paterson et al, 2000 ⁸⁰					Poor/?	Poor/?	Free

	MOS-6A	Paterson et al, 2000 ⁸⁰			Poor/?	Poor/?	Free
Health status	EXACT- PRO	Leidy et al, 2014 ⁸²			Poor/?		Not free for commercial
		Leidy et al, 2011 ⁶⁹	Poor/+		Poor/?	Poor/?	use
	GOLD + SSI	Hutchinson et al, 2010 ⁸³		Poor/+			Free
ADL	MRADL	Yohannes et al, 2005 ⁸¹		Poor/?			Not free for commercial use
	LCADL	Miravitlles et al, 2011 ⁷⁹		Fair/?	Poor/?		Free
General symptoms	CASA-Q	Monz et al, 2010 ⁸⁴			Poor/+	Poor/?	No information

^aADL = activities of daily living; BDI/TDI = Baseline Dyspnea Index and Transition Dyspnea Index; BPQ = Breathing Problems Questionnaire; CASA-Q = Cough and Sputum

Assessment Questionnaire; CAT = COPD [Chronic Obstructive Pulmonary Disease] Assessment Test; CCQ = Clinical COPD Questionnaire; COPDSS = COPD severity score;

765 CRQ = Chronic Respiratory Disease Questionnaire; eMRC = extended Medical Research Council (MRC); EQ-5D = EuroQol 5D; EXACT-PRO = Exacerbations of Chronic

Pulmonary Disease Tool–Patient-Reported Outcome; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HRQL = Health-Related Quality of Life; LCADL = London

767 Chest Activities of Daily Living Scale; mBorg = modified Borg Scale; mMRC = modified MRC; MOS-6A = Medical Outcomes Study 6-Item General Health Survey; MRADL =
 768 Manchester Respiratory Activities of Daily Living Questionnaire; MYMOP = Measure Your Medical Outcome Profile; NHP = Nottingham Health Profile; SF-6D = Short-Form 6D;

769 SGRQ = St George Respiratory Questionnaire; SSI = Symptom Severity Index; VAS = visual analog scale; + = positive; - = negative; ? = indeterminate.

771 **Table 4.**

- 772 Consensus-Based Standards for the Selection of Health Status Measurement Instruments (COSMIN) Evaluation, Quality of the Measurement
- 773 Property, and Cost of Clinical Outcomes^a

Outcome	Outcome	Study	Reliabil	ity	V	alidity	Responsiven ess	Cost
	Measure		Internal Consistency	Test- Retest	Criterion Validity	Construct Validity (Hypothesis Testing)		
Oxygen saturation	SpO ₂ (%)	Güryay et al, 2007 ⁷⁰			Fair/+	Poor/?		Not free
		Kelly et al, 2001 ⁹⁰			Fair/+	Poor/+		
Lung function	PEF (pp)	Emerman et al, 1996 ⁹¹				Poor/+	Fair/+	Not free
		Güryay et al, 2007 ⁷⁰				Poor/?		
	FEV ₁ (pp or L)	Güryay et al, 2007 ⁷⁰			Poor/?	Poor/?		Not free
		Aaron et al, 2002 ⁷²					Poor/?	
		White et al, 2005 ⁹²				Poor/?		
	FVC (pp)	Güryay et al, 2007 ⁷⁰				Poor/?		Not free
	CRS	Morillo et al, 2013 ⁹³			Fair/+			Not free
Body composition	BMI (kg/m ²)	Tsimogianni et al, 2009 ⁹⁴			Poor/+			Free
Physical activity	Time spent in weight- bearing activities (min)	Pitta et al, 2006 ⁹⁵				Poor/+		Not free

^aBMI = body mass index; CRS = computerized respiratory sounds; FEV₁ = forced expiratory volume in 1 s; FVC = forced vital capacity; PEF = peak expiratory flow; pp =

percentage of predicted normal value; SpO_2 = peripheral oxygen saturation; + = positive; - = negative; ? = indeterminate.




Figure.

Flow diagram of the studies assessing the measurement proprieties of the outcome measures used in the pulmonary rehabilitation (PR) of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (phase 2).